MiMedx Group, Inc., the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced its record results for the quarter ended March 31, 2017.

First Quarter 2017 Highlights

• Revenue grew 36% over Q1 2016 revenue

• Revenue of $72.6 million exceeds upper end of MiMedx guidance range

• Wound Care revenue of $54.9 million grew 40% over Q1 2016

• Surgical, Sports Medicine and Orthopedics revenue of $17.7 million grew 26% over Q1 2016

• 24th of last 25 quarters of meeting or exceeding revenue guidance

• Gross profit margin of 88%

• Net income of $4.3 million is a 261% increase over Q1 2016

• Positive Net Cash Flow From Operations of $10.6 million compared to negative $1.0 million in Q1 2016

• 21st consecutive quarter of positive Adjusted EBITDA

• Adjusted Net Income* of $7.4 million is a 51% increase over Q1 2016

• Adjusted EBITDA* of $12.4 million is a 37% increase over Q1 2016

* See the accompanying tables for definitions of each Non-GAAP metric. Reconciliations of GAAP Net Income to Adjusted EBITDA, GAAP Gross Margin to Adjusted Gross Margin, and GAAP Net Income to Adjusted Net Income and Adjusted Diluted Net Income Per Share appear in the tables below. These non-GAAP measures include, but are not limited to, adjustments for non-cash charges associated with purchase accounting related to the Stability Biologics acquisition, normalization of tax expense, one-time non-recurring cash charges and share based compensation expense.

Results for First Quarter Ended March 31, 2017
The Company recorded record revenue for the 2017 first quarter of $72.6 million, a $19.2 million or 36% increase over 2016 first quarter revenue of $53.4 million. The Company's gross margin for the quarter ended March 31, 2017, was 88%, as compared to the 85% gross margin in the first quarter of 2016. Net Income for the first quarter of 2017, was $4.3 million, or $.04 per diluted common share, a $3.1 million or 261% increase, as compared to Net Income of $1.2 million, or $0.01 per diluted common share in the first quarter of 2016.  Adjusted EBITDA* for the quarter ended March 31, 2017, was $12.4 million, a $3.3 million or 37% improvement, as compared to Adjusted EBITDA* of $9.1 million for the first quarter of 2016. 

Management Commentary on Results
Parker H. "Pete" Petit, Chairman and CEO stated, "We are pleased to have exceeded the top end of our revenue guidance and to have recorded very solid performance on our revenue and profit growth. In light of the impact of the normal seasonality that the market experiences in the first quarter of the year, we are especially satisfied with our growth. With respect to our profit performance, our first quarter GAAP Net Income grew by well over 250% compared to Q1 2016, our Adjusted Net Income grew by 51% over the first quarter of 2016, and our Adjusted EBITDA* grew by 37% over Q1 2016. We expect our profit metrics as a percent of revenue to increase as the year progresses."

Bill Taylor, President and COO, said, "Both of our sales verticals had strong growth with Wound Care revenue increasing by 40% over the first quarter of 2016 and SSO growing by 26% compared to the first quarter of last year. We are also extremely pleased with our strong operating cash flow performance compared to last year's first quarter. Our cash flow from operations was $10.6 million, compared to a negative $1.0 million in the first quarter of 2016.  We had another very favorable decline in Days Sales Outstanding in our Accounts Receivable during the quarter, which continued the trend experienced in the last half of 2016."

"Our three new products introduced during 2016, EpiCord®, our new dehydrated human umbilical cord allograft, AmnioFill®, the first product in the MiMedx placental collagen matrix product family to be commercially launched, and OrthoFlo Lyophilized, an extension of the Company's amniotic fluid product family, are proving to be very impactful in pursuing our market penetration initiatives. We believe the performance of these new products during the first quarter is solid evidence of the contribution they will deliver during 2017 and beyond," added Taylor.

Petit commented, "I believe that our shareholders are beginning to realize the very productive asset base that the Company has developed over the last six years.  We have developed the management staff, the technology and the intellectual property to smoothly transition our focus towards becoming predominantly a biopharma company.  In addition, our asset base includes the technology differentiator in that it embodies over 220 proteins, the primary methods of action for which we have scientifically proven.  We have also demonstrated the clinical effectiveness of these proteins through approximately 30 different peer reviewed publications.  That is a significant head start in terms of having the resources necessary to proceed down the Investigational New Drug/Biologics License Application regulatory pathways for numerous new therapeutic applications of our technology.  As shareholders should be aware, we are completing the phase IIb studies on our first IND for plantar fasciitis.  We will soon be entering our phase III trials.  We have indicated our plans to very shortly file additional INDs on other sports medicine related therapies.  We have indicated some of the areas of focus that will be longer-term opportunities for the Company from the same regulatory approval process.  Your management is quite enthusiastic about our recently announced strategic focus.  We will continue to advise you as our progress in this new strategic area develops."

Share Repurchase Program
From the May 2014 inception of the Share Repurchase Program through December 31, 2016, the Company acquired $56.1 million in repurchased shares. During the first quarter of 2017, the Company continued to acquire its shares through the Company's Share Repurchase Program by repurchasing an additional $12.6 million of its shares. Also during the quarter, the Company's Board of Directors authorized an increase of $20 million to the Company's Share Repurchase Program. With the first quarter authorizations made by the MiMedx Board, the total amount authorized for the Company's Share Repurchase Program to date is $86 million.

Liquidity and Cash Flow
Cash on hand as of March 31, 2017, was $30.9 million, as compared to $15.1 million as of March 31, 2016. Net working capital as of March 31, 2017 decreased $3.5 million to $72.3 million, as compared to $75.8 million as of December 31, 2016.  The Company recorded positive net cash flow from operating activities of $10.6 million for the quarter ended March 31, 2016 due primarily to increased Adjusted EBITDA*.

GAAP Earnings
The Company recorded Net Income of $4.3 million for the quarter ended March 31, 2017, or $0.04 per diluted common share, as compared to Net Income of $1.2 million, or $0.01 per diluted common share, for the quarter ended March 31, 2016.  R&D expenses for the first quarter of 2017 were $4.2 million or 6% of Net Sales, an increase of $1.7 million over first quarter 2016 R&D expenses of $2.5 million.

Selling, general and administrative expenses for the first quarter of 2017 were $52.9 million, a $12.3 million increase over first quarter of 2016 SG&A expenses of $40.6 million.  Increases in SG&A were due to the continuation of the buildup of the Company's direct sales force in Wound Care and SSO sales channels, as well as litigation costs. 

Revenue Breakdown
The Company distinguishes revenue in two categories: (1) Wound Care and (2) SSO, which includes Original Equipment Manufacturer applications. For first quarter of 2017, Wound Care revenue was $54.9 million, representing 75.6% of total revenue, and SSO (including OEM) revenue was $17.7 million, representing 24.4% of total revenue.

Second Quarter and Full Year 2017 Guidance Highlights
MiMedx provided its revenue guidance for the second quarter of 2017, increased the low end of its revenue guidance range for full year 2017, and reiterated the remaining full year 2017 guidance that was previously communicated. The Company's second quarter and full year 2017 guidance includes:

• Second quarter of 2017 revenue forecasted to be in the range of $73.5 to $75 million

• 2017 revenue guidance in the range of $303.5 to $307 million

• Gross profit margins for 2017 expected to be in the range of 86% to 88%

• 2017 Operating Earnings forecasted to grow by 90% or greater

• GAAP EPS for 2017 projected to be in the range of $0.18 to $0.20

• Adjusted EPS* for 2017 projected to be in the range of $0.31 to $0.33

• 2017 GAAP Net Earnings expected to grow in excess of 95%

• 2017 Adjusted EBITDA* expected to be in the range of 21% to 23% of revenue

"Our strong first quarter performance and market momentum gives us a high level of confidence in meeting or exceeding our expectations for 2017," concluded Petit.